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A prospective study was conducted over a 30-month period, in which fecal specimens from 6,750 patients
were submitted to the Department of Microbiology at St. Vincent’s Hospital, Sydney, Australia. Trophozoites
of Dientamoeba fragilis were detected in 60 (0.9%) patients by permanent staining, and confirmation was
performed by PCR. Gastrointestinal symptoms were present in all patients, with diarrhea and abdominal pain
the most common symptoms. Thirty-two percent of patients presented with chronic symptoms. The average age
of infected patients was 39.8 years. No correlation was found between D. fragilis and Enterobius vermicularis, a
proposed vector of transmission for D. fragilis. The genetic diversity of 50 D. fragilis isolates was examined by
PCR, and the PCR products were analyzed for the presence of restriction fragment length polymorphisms.
These results showed no variation in the small-subunit rRNA gene and demonstrated a single genotype for all
Australian isolates. This study shows the potential pathogenic properties of D. fragilis and the need for all
laboratories to routinely test for this organism.
Dientamoeba fragilis is a trichomonad parasite found in the
gastrointestinal tract of humans and implicated as a cause of
gastrointestinal disease. Dientamoeba fragilis has been found in
most parts of the world in both rural and cosmopolitan areas
(10). The prevalence of this organism in Australia varies great-
ly, from 0.4% to 16.8%, in patients presenting with gastroin-
testinal complaints (1, 22).
No cyst stage has been observed, and only the trophozoites
are detected in stool samples. Definitive diagnosis is based on
prompt fixation and permanent staining, as the trophozoites
degenerate rapidly, within hours of been passed, and demon-
stration of their characteristic nuclear structure cannot be
achieved in unstained preparations (24). Daily shedding of
D. fragilis trophozoites has been shown to be highly variable,
with intermittent shedding occurring regularly, necessitating
multiple sampling for maximum chances of detection (20).
Molecular techniques for the diagnosis of D. fragilis show
much promise, with PCR demonstrating excellent sensitivity
and specificity (18). Such techniques have been used success-
fully for the diagnosis of other pathogenic protozoa (11, 19).
Molecular genotyping and sequence analysis have demon-
strated that D. fragilis exists as two genetically distinct forms (9,
15, 18, 26). Stark et al. (18) sequenced the SSU rRNA gene of
seven Australian D. fragilis isolates, and the data generated
from the seven showed no variation among them. These ob-
servations support the notion that D. fragilis is a clonal species.
The sequences from the Australian isolates, however, differed
from the sequence of the D. fragilis strain Bi/PA (ATCC 30948;
GenBank accession no. U37461) and were found to be similar
to those found in a recent study in the Netherlands (15). The
true incidence of the wild-type and variant forms in Australia
needs to be established and to determine if such variation has
any influence on the pathogenicity of the parasite.
A prospective study was undertaken to determine the preva-
lence and clinical relevance of D. fragilis infections in an Aus-
tralian population and to determine the genetic diversity of
these isolates obtained at the small-subunit (SSU) rRNA gene
locus.
MATERIALS AND METHODS
Fecal specimens. All fecal specimens submitted to the Department of Micro-
biology at St. Vincent’s Hospital, Sydney, for investigation of diarrhea from
March 2002 until July 2004 were included in the study. One to three specimens
per patient were examined. Specimens from outpatients were collected by the
patient and submitted to the laboratory as a fresh specimen along with a portion
mixed with sodium acetate-acetic acid-formalin (SAF) preservative. Specimens
from inpatients or received without a portion fixed in SAF were immediately
preserved in SAF upon arrival at the laboratory.
Microbiological investigation. Fecal specimens were cultured for the following
bacterial pathogens: Salmonella spp., Shigella spp., Campylobacter spp., Aeromo-
nas spp., Yersinia spp., and Clostridium difficile, and culture for Vibrio spp. was
performed where indicated if a patient had history of travel to an endemic area,
using standard laboratory procedures and techniques.
An immunochromatographic screening test, the Adeno/Rota STAT-PAK
(Chembio Diagnostic Systems Inc., Sydney) for the detection of adenovirus and
rotavirus antigen in feces was used according to the manufacturer’s recommen-
dations.
Approximately 1 g of feces was placed into SAF and fixed overnight. The fixed
specimens were then stained using a modified iron hematoxylin stain, incorpo-
rating a carbol fuchsin step to detect coccidia (Fronine, Australia), according to
the manufacturer’s recommendations. Formalin-ethyl acetate concentration was
used for the detection of any helminth ova. In addition, any specimens from
human immunodeficiency virus-infected patients were examined for microspo-
ridial spores using the Uvitex 2B stain (21).
PCR for D. fragilis. All specimens where D. fragilis was detected by permanent
stain underwent DNA extraction and PCR for D. fragilis-specific DNA using
primers DF400 and DF1250 as previously described (18).
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Restriction fragment length polymorphism. Restriction fragment length poly-
morphism (RFLP) analysis was undertaken on all positive PCR products. Eight
l of the PCR product was digested with 10 U of DdeI (Roche, Australia) in a
final volume of 15 l for 1 h at 37°C. Samples were analyzed by electrophoresis
on 3% ReadyAgarose gels (Bio-Rad, Sydney).
Follow-up data. Clinical data were collected from all patients diagnosed with
D. fragilis. Wherever possible multiple, sticky-tape tests, two to five tapes per
patient, were conducted for the detection of Enterobius vermicularis.
Control group. A control group comprising 900 fecal samples from patients
without diarrhea or symptoms of gastroenteritis (submitted for occult blood
testing and fecal reducing substances) were used. These specimens were pro-
cessed as above and stained using a modified iron hematoxylin stain. Ninety of
these specimens were randomly selected and underwent PCR using D. fragilis-
specific primers as described by Stark et al. (18).
Questionnaire. Questionnaires were distributed to 26 laboratories in the Syd-
ney metropolitan area. Information requested for the calendar years 1996 to
2002 included total number of fecal samples processed for ova cysts and para-
sites, total number of specimens positive for D. fragilis, use of permanent stain,
fixation method used in this period, and the situation in which a fixation method
would be used.
RESULTS
A total of 6,750 patients submitted fecal specimens between
March 2002 and July 2004. Sixty patients were diagnosed with
D. fragilis infection from the permanent stains, giving a prev-
alence of infection of 0. 9%. The results found in this study are
summarized in Table 1.
Of the 60 patients infected with D. fragilis, six (10%) had a
history of recent overseas travel; three to Southeast Asia, one
to Timor, one to Fiji, and one to Papua New Guinea. The re-
maining 54 of 60 patients (90%) had no recent history of travel
outside Australia.
A total of 24/60 (40%) patients had other parasites detected
(Table 2). No coccidian parasites were detected. The only oth-
er pathogenic protozoan was Giardia intestinalis, which was
found concurrently with D. fragilis in three samples. The re-
maining 36 patients (60%) had only D. fragilis detected. All fe-
cal samples were semiformed or liquid.
The most frequent clinical symptoms associated with D. fra-
gilis infection were diarrhea, abdominal pain, and loose bowel
movements. Vomiting was only reported in one patient. Chron-
ic persistent symptoms were common, with 19/60 (32%) pa-
tients having diarrhea of over 2 weeks in duration, and one
patient claimed to have intermittent diarrhea for several years.
Five patients had recurrent D. fragilis infections. One patient
was diagnosed with irritable bowel syndrome. All patients were
symptomatic. Only one patient (human immunodeficiency vi-
rus infected) was immunosuppressed, with all the others being
immunocompetent. No microsporidia were detected in the hu-
man immunodeficiency virus-infected patient.
Thirty patients were female and 30 were male, with the age
range being 3 to 79 years (Fig. 1). The average age was 39.8
years, with a median of 44.5 years. No seasonal variation was
found with D. fragilis infection.
No helminth ova were detected in the 60 patients using a
formalin-ethyl acetate concentration technique, and no En-
terobius vermicularis adults or ova were found; 33/60 (55%)
patients submitted a sticky-tape test for E. vermicularis ova, all
of which were negative.
No bacterial pathogens were isolated from the patients with
D. fragilis infection. The immunochromatographic tests for
both adenovirus and rotavirus were also negative for all of the
patients.
PCR was performed on 54 of the 60 samples; for six speci-
mens there was a delay (7 days) in undertaking the DNA
extraction, so these specimens were excluded from PCR test-
ing. A specific D. fragilis PCR product of approximately 870 bp
was detected in 50 out of 54 samples using the D. fragilis-
specific primers designed by Stark et al. (18). RFLP was per-
formed on the 50 positive PCR samples. All gave identical
RFLP patterns (data not shown).
Nine hundred fecal samples from patients without gastroin-
testinal symptoms were used as a control group. No D. fragilis
was detected by permanent staining. However, nonpathogenic
protozoa were detected in the control group. Blastocystis homi-
nis was found in 47 (5.2%) patients and Endolimax nana in 19
(2.1%), while Blastocystis hominis and Endolimax nana were
found concurrently in 12 (1.3%) patients. One patient (0.1%)
was found to have Entamoeba hartmanni. PCR using D. fragilis-
specific primers was undertaken on 90 samples randomly cho-
sen from the control group. All 90 specimens were negative for
D. fragilis DNA by PCR.
Of the 26 laboratories that were sent the questionnaire, only
11 responded. The remaining 15 laboratories were contacted,
and four agreed to participate in a phone interview using the
same questions as on the written questionnaire. Of the 15
laboratories it was determined that only three in the Sydney
metropolitan area routinely performed permanent stains on
feces for ova, cysts, and parasite examinations.
DISCUSSION
Dientamoeba fragilis has a worldwide cosmopolitan distribu-
tion. In Australia and New Zealand, the reported prevalence
rate ranges from 0.4% in western Australia (1) and 1.5% in an
urban community in Brisbane (17) to 2.2% in Christchurch,
New Zealand (14), and 16.8% in suburban Sydney (21). A
longitudinal study of parasite infections in Aboriginal children
from the Queensland outback found a prevalence of 5.0% for
D. fragilis (23). In this present study a prevalence of 0.9%
was found; this is in stark contrast to the prevalence of 16.8%
that was found by Walker et al. (22) in the Sydney suburb of
French’s Forrest.
In this study, D. fragilis infection was closely associated with
diarrhea, abdominal pain, and loose bowel movements. All
patients with D. fragilis infection were symptomatic, and bac-
terial and viral causes of these symptoms are unlikely, as rou-
tine microbiological cultures and adenovirus and rotavirus test-
ing were negative. However, testing for pathogenic Escherichia
coli or norovirus was not undertaken. Three patients were also
infected with Giardia intestinalis, which could have caused the
gastrointestinal symptoms described in those patients.
One important finding of this study was that chronic persis-
tent symptoms were common. Thirty-two percent of patients
had diarrhea for more than 2 weeks, and one patient claimed
to have had intermittent diarrhea for several years. Five pa-
tients had recurrence of symptoms during the course of the
study. It is unknown whether these recurrences were due to
treatment failure or reinfection from a common source. One
patient was diagnosed with irritable bowel syndrome and was
subsequently found to have D. fragilis infection. A recent Aus-
tralian study by Borody et al. (2) showed a link between D.
fragilis and irritable bowel syndrome. Twenty-one patients di-
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TABLE 1. Summary of results from patients with D. fragilis infection
Patient
no.
Age
(yr) Sex
a Description
of fecesb
Concentrate
ethyl acetatec
Sticky-tape test
(no. of tapes)
Bacterial
cultured
Rotavirus/
adenoviruse Clinical symptoms
f Other parasite(s) present
1 15 F Uf Neg N/A NSP Nd/Nd PUO, diarrhea No
2 6 M Uf Neg Neg (4) NSP Nd/Nd Abdominal pains No
3 52 F Uf Neg Neg (2) NSP Nd/Nd Gastroenteritis, Giardia? No
4 7 M Uf Neg Neg (5) NSP Nd/Nd Diarrhea, Giardia? E. nana
5 7 M Uf Neg Neg (3) NSP Nd/Nd Diarrhea, Giardia? E. nana
6 47 M Uf Neg N/A NSP Nd/Nd Chronic GIT symptoms I. butschlii, E. nana, E. hominis,
B. hominis
7 27 M Uf Neg Neg (3) NSP Nd/Nd Gastroenteritis I. butschlii, E. nana, E. hominis,
B. hominis, E. coli, G.
intestinalis
8 58 F Uf Neg Neg (2) NSP Nd/Nd Gastroenteritis No
9 7 F Uf Neg N/A NSP Nd/Nd Diarrhea B. hominis
10 58 F Uf Neg Neg (2) NSP Nd/Nd Gastroenteritis No
11 54 F Uf Neg Neg (2) NSP Nd/Nd Diarrhea 3–4/52,
abdominal pains
No
12 53 M Uf Neg N/A NSP Nd/Nd Gastroenteritis No
13 8 F Fl Neg Neg (4) NSP Nd/Nd Gastroenteritis, Giardia? No
14 9 F Uf Neg Neg (3) NSP Nd/Nd Gastroenteritis, previous
D. fragilis
B. hominis
15 33 F Uf Neg N/A NSP Nd/Nd Recurrent gastroenteritis,
parasites?
No
16 29 F Fl Neg N/A NSP Nd/Nd Diarrhea, recent travel to
Southeast Asia
No
17 34 F Uf Neg Neg (2) NSP Nd/Nd Diarrhea for 5 weeks No
18 45 M Uf Neg Neg (3) NSP Nd/Nd Chronic gastroenteritis E. nana, B. hominis
19 45 M Uf Neg N/A NSP Nd/Nd Diarrhea E. nana, B. hominis
20 9 F Uf Neg Neg (5) NSP Nd/Nd Persistent diarrhea No
21 74 M Uf Neg Neg (2) NSP Nd/Nd Persistent loose bowel
movements, overseas
travel
No
22 45 M Uf Neg Neg (3) NSP Nd/Nd Previous D. fragilis B. hominis
23 49 F Uf Neg N/A NSP Nd/Nd Diarrhea No
24 63 F Uf Neg N/A NSP Nd/Nd Diarrhea B. hominis
25 74 M Uf Neg N/A NSP Nd/Nd Previous D. fragilis,
symptomatic
No
26 46 M Fl Neg N/A NSP Nd/Nd Irritable bowel syndrome? No
27 45 F Uf Neg N/A NSP Nd/Nd Abnormal stools, camping
in Fiji
No
28 36 F Fl Neg Neg (2) NSP Nd/Nd Diarrhea, abdominal pains No
29 47 F Fl Neg Neg (2) NSP Nd/Nd Diarrhea No
30 10 M Uf Neg N/A NSP Nd/Nd Chronic gastroenteritis B. hominis
31 62 F Uf Neg Neg (3) NSP Nd/Nd Intermittent diarrhea for
years, Giardia?
B. hominis
32 75 M Uf Neg Neg (4) NSP Nd/Nd Ongoing loose bowel
movements, previous D.
fragilis
No
33 38 M Uf Neg N/A NSP Nd/Nd Watery diarrhea for 3
weeks, travel to
Vietnam
No
34 64 M Uf Neg Neg (3) NSP Nd/Nd Diarrhea, parasites? No
35 38 F Fl Neg N/A NSP Nd/Nd Diarrhea No
36 11 F Uf Neg Neg (2) NSP Nd/Nd Diarrhea and vomiting No
37 45 M Uf Neg N/A NSP Nd/Nd Diarrhea, recent trip to
Papua New Guinea
No
38 45 M Uf Neg N/A NSP Nd/Nd Loose stools No
39 7 F Fl Neg Neg (2) NSP Nd/Nd Diarrhea G. intestinalis
40 49 M Uf Neg Neg (3) NSP Nd/Nd Diarrhea, fever No
41 75 M Uf Neg N/A NSP Nd/Nd Recurrent D. fragilis
infection
No
42 68 F Uf Neg Neg (2) NSP Nd/Nd Diarrhea, abdominal pain,
Giardia?
B. hominis
43 4 M Uf Neg Neg (4) NSP Nd/Nd Abdominal pain, diarrhea
intermittently for 3 mo
G. intestinalis, B. hominis
44 25 M Fl Neg Neg (2) NSP Nd/Nd Diarrhea B. hominis
45 69 F Uf Neg N/A NSP Nd/Nd Diarrhea, abdominal pain No
46 79 F Uf Neg Neg (2) NSP Nd/Nd Diarrhea 1 week No
47 41 F Fl Neg N/A NSP Nd/Nd Diarrhea, Giardia? B. hominis
48 56 F Uf Neg N/A NSP Nd/Nd Diarrhea, Giardia? No
Continued on following page
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agnosed with irritable bowel syndrome and concurrent D. fra-
gilis infection were treated with iodoquinol and doxycycline.
Complete elimination of D. fragilis with marked clinical im-
provement occurred in the majority of patients.
Ten percent of patients diagnosed with D. fragilis infection
had a history of recent overseas travel, including Southeast
Asia, Papua New Guinea, Timor, and Fiji. Dientamoeba fragilis
has been implicated as a cause of diarrhea in returning Swedish
travelers, with Norberg et al. (13) finding 63% of patients in a
retrospective study had been infected outside the country.
Most patients were infected in Africa, South America, and the
Middle East.
No parasites were detected by formalin-ethyl acetate con-
centrations performed on fecal specimens from the D. fragilis-
infected patients. Fifty-five percent of the patients submitted
multiple tape tests for the detection of Enterobius vermicularis
ova, and no E. vermicularis ova were detected. Many research-
ers have postulated that pinworm is a vector for D. fragilis
transmission. Burrows and Swerdlow (3) were the first to pro-
pose that E. vermicularis might be a vector for D. fragilis. Sev-
eral other researchers also found a higher than expected con-
currence of D. fragilis and E. vermicularis coinfections (4, 5, 16,
26).
In contrast, a recent study of 25 pediatric cases of D. fragilis
found no infections were associated with E. vermicularis (7).
These results, along with the findings from this present study,
would argue against the hypothesis that E. vermicularis plays a
significant role in the transmission of D. fragilis. Most studies
that have examined D. fragilis infection have inadequately ex-
amined for E. vermicularis. It has yet to be proven what role
helminth ova play in the transmission of D. fragilis. Further
study is required to ascertain the true mode of transmission of
this organism.
Other enteric protozoa were present in 40% of patients with
D. fragilis infection. The most common organism was B. homi-
nis. Other protozoa present included E. nana, E. hominis, E.
coli, Iodamoeba butschlii, and G. intestinalis. All of these par-
FIG. 1. Prevalence of D. fragilis in different age groups.
TABLE 1—Continued
Patient
no.
Age
(yr) Sex
a Description
of fecesb
Concentrate
ethyl acetatec
Sticky-tape test
(no. of tapes)
Bacterial
cultured
Rotavirus/
adenoviruse Clinical symptoms
f Other parasite(s) present
49 61 M Fl Neg N/A NSP Nd/Nd Diarrhea, abdominal pain,
Giardia?
B. hominis
50 43 F Uf Neg N/A NSP Nd/Nd Diarrhea, recurrent
Dientamoeba/Blastocystis
B. hominis
51 3 M Uf Neg Neg (5) NSP Nd/Nd Diarrhea G. intestinalis, B. hominis
52 56 F Uf Neg Neg (3) NSP Nd/Nd Intermittent diarrhea,
abdominal pain
No
53 43 M Fl Neg N/A NSP Nd/Nd Diarrhea No
54 20 M Fl Neg Neg (2) NSP Nd/Nd Diarrhea, abdominal pain B. hominis
55 22 M Uf Neg N/A NSP Nd/Nd Chronic diarrhea, 2 wk
duration
B. hominis
56 47 M Uf Neg Neg (2) NSP Nd/Nd Diarrhea, cramps B. hominis, E. nana, E. coli
57 32 M Fl Neg Neg (2) NSP Nd/Nd Loose motions and wind
for 6 mo
No
58 42 F Uf Neg Neg (3) NSP Nd/Nd Diarrhea, 1 wk B. hominis
59 31 M Uf Neg N/A NSP Nd/Nd Diarrhea after visit to
Timor, mild chronic
gastritis 4 wk
ulcerative proctitis
No
60 44 F Uf Neg N/A NSP Nd/Nd Abdominal cramps, wind,
loose movements
No
a F, female; M, male.
b Un, unformed; Fl, fluid.
c Neg, negative.
d NSP, no significant bacterial pathogens isolated.
e Nd, not detected by immunochromatographic assay.
f PUO, pyrexia unknown origin; GIT, gastrointestinal.
TABLE 2. Parasites found in 24 patients with D. fragilis infection
Parasite(s) No. ofpatients
Blastocystis hominis ..............................................................................14
Endolimax nana.................................................................................... 2
B. hominis, E. nana.............................................................................. 2
G. intestinalis, B. hominis .................................................................... 2
B. hominis, E. nana, Entamoeba coli ................................................. 1
G. intestinalis......................................................................................... 1
G. intestinalis, I. butschlii, E. nana, E. hominis, B. hominis,
E. coli................................................................................................. 1
G. intestinalis, I. butschlii, E. nana, B. hominis ................................ 1
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asites are known to be transmitted via the fecal-oral route.
Other researchers have found similar rates of coinfection of
D. fragilis with other parasites that are transmitted via the
fecal-oral route. Windsor et al. (25) found 54% of patients with
D. fragilis had other parasites or enteropathogens present.
These findings provide circumstantial evidence to support a
hypothesis for a fecal-oral route of transmission for D. fragilis.
No D. fragilis trophozoites were detected in the control
group of 900 smaples from patients without gastrointestinal
symptoms. This is in contrast to other studies, where D. fragilis
was detected in patients with no clinical symptoms (6) and in a
case-control study on gastroenteritis from the Netherlands,
where D. fragilis was recovered more frequently from controls
than case patients (8). These findings may be attributed to the
fact that asymptomatic carriage of intestinal protozoa can of-
ten occur.
The permanent stained smears positive for D. fragilis were
confirmed by PCR. A sensitivity of 93% (50/54 samples) was
obtained using a previously published method (18). All 90 neg-
ative samples from the control group failed to produce a PCR
product.
Sequence data generated in several studies supports the
notion for at least two distinct genetic variants of D. fragilis.
Johnson and Clarke (9) estimated a sequence divergence of
2% between the two SSU rRNA genotypes of D. fragilis; this
was later supported by Peek et al. (15) by sequencing a 558bp
region of the SSU rDNA. Sequence data generated by Stark
et al. (18) from the entire SSU rDNA region of Australian
isolates of D. fragilis showed a greater sequence divergence of
4% between the Australian genotypes and the D. fragilis strain
Bi/PA (ATCC 30948). All Australian strains sequenced were
identical, which supports the notion that D. fragilis is a clonal
species.
The Australian isolates were found to be similar to those
found in a recent study in the Netherlands and do not contain
the polymorphic DdeI restriction site (CTTAG) at position
644 found in D. fragilis strain Bi/PA (15). RFLP analysis was
undertaken on all 50 Australian samples to determine the
genotypes present in the Australian population and the extent
of genetic diversity. The PCR used in this study amplifies the
SSU rRNA region from approximately position 400 to position
1270. This PCR product contains two DdeI restriction sites
(CTTAG) that are present in the D. fragilis ATCC 30948 strain
yet are absent in the Australian genotypes. All 50 D. fragilis
samples showed no variation and corresponded to genotype A.
These findings suggest that D. fragilis in Sydney, Australia,
displays only a single genotype in fecal samples from various
groups, including inpatients, outpatients, and travelers. Fur-
ther studies are needed to identify the presence of other geno-
types throughout Australia.
Dientamoeba fragilis has no recognized cyst stage, and as
such, diagnosis is dependent on detecting the trophozoites. As
these trophozoites degenerate rapidly prompt fixation of the
specimen is necessary (26). Successful diagnosis of D. fragilis is
closely associated with the use of permanent stains of fecal
smears. Failure to use permanent staining and fixation tech-
niques will inevitably preclude identification of D. fragilis. The
aim of the questionnaire sent to the Sydney laboratories was to
determine how many laboratories routinely undertake perma-
nent staining and therefore how many laboratories are able to
report the presence of D. fragilis. Of the 26 Sydney laborato-
ries, 58% (15/26) participated in the survey, and only three
routinely performed permanent staining for ova, cyst and par-
asites on fecal specimens. Those three laboratories were the
only institutions that detected D. fragilis in routine samples.
Therefore the true extent of D. fragilis infection must be greatly
underestimated as most laboratories do not use techniques to
adequately identify this organism.
This is the first prospective study of D. fragilis in Australia to
examine clinical data in addition to the genetic diversity of the
isolates. Diagnosis was based on permanent staining of fixed
fecal smears and confirmed by PCR which demonstrated good
sensitivity. All patients infected with D. fragilis were symptom-
atic and D. fragilis infections were most commonly associated
with diarrhea and abdominal pain. Concurrent infections with
other protozoa were common, occurring in 40% of samples.
The occurrence of D. fragilis with other protozoa that are
transmitted via the fecal-oral route would strengthen the case
for D. fragilis also being transmitted via this route. No corre-
lation was found with E. vermicularis or any other helminths,
questioning the role, if any, pinworm has in the transmission of
D. fragilis.
The genetic diversity within 50 samples was examined by
PCR followed by RFLP. These data indicated that a single
genotype of D. fragilis was represented, one that is genetically
different from the North American D. fragilis strain Bi/PA
(ATCC 30948). The evidence that D. fragilis is a pathogen is
overwhelming (2, 10, 13, 16, 26), and as such all laboratories
should attempt to identify this protozoan by the use of perma-
nent staining techniques or molecular methods.
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